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Membrane fusion is a key event in exocytosis of neurotransmitters and hor-
mones stored in intracellular vesicles. In this process, soluble N-ethylmalei-
mide sensitive factor attachment protein receptor (SNARE) proteins are
essential components of the exocytotic molecular machinery, while lipids have
been seen traditionally as structural elements. However, the so-called sig-
nalling lipids, such as sphingosine and arachidonic acid, interact with
SNAREs and directly modulate the frequency and mode of fusion events.
Interestingly, recent work has proved that the sphingosine analogue FTY-720,
used in the treatment of multiple sclerosis, mimics the effects of signalling
lipids. In the present Review, we discuss recent investigations suggesting that
endogenous signalling lipids and synthetic analogues can modulate important
physiological aspects of secretion, such as quantal release, vesicle recruitment
into active sites, vesicle transport and even organelle fusion in the cytosol.
Therefore, these compounds are far from being merely structural components
of cellular membranes.
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The fusion of the vesicles containing neurotransmitters
and hormones with the plasma membrane to release
their content during the process of exocytosis is a key
event underlying the function of the neuronal and
endocrine systems. In essence, this is a multisequential
process involving the cytoskeletal-mediated transport
of vesicles [1,2], their docking and final release of neu-
rotransmitters through the interactions of soluble
N-ethylmaleimide sensitive factor attachment protein
receptor (SNARE) proteins and the lipids constituting
the vesicular and plasma membrane [3,4].
The lipids within the membranes were initially
assumed to play a passive role, but recent results
indicate that a class known as signalling lipids directly
modulate SNARE function, and may play important
roles in the physiology of neurosecretion [5–7].
Signalling lipids that modulate SNARE function
include arachidonic acid (AA) and sphingosine. AA is
generated from a variety of phospholipid molecules by
phospholipase-A2 or diacylglycerol lipase whereas sph-
ingosine is produced from sphingolipids. AA primarily
seems to target t-SNARE protein syntaxin-1 [8,9],
which is anchored to the plasma membrane, whereas
sphingosine interacts with synaptobrevin, which is the
complementary v-SNARE anchored to the vesicle.
Both AA and sphingosine seem to enhance exocytosis
Abbreviations
PUFAs, polyunsaturated fatty acids; SMase, sphingomyelinase; SNAP-25, synaptosomal-associated protein of 25 kDa; SNARE, soluble
N-ethylmaleimide sensitive factor attachment protein receptor.
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of both neurotransmitters and hormones by promoting
formation of SNARE complexes [10].
Interestingly, a structural analogue of sphingosine of
fungal origin, FTY-720, also known as Fingolimod,
has been approved for the oral treatment of multiple
sclerosis [11], one of the most frequent disorders of the
CNS. In this case, this substance is phosphorylated
and binds to sphingosine-1-phosphate receptors, caus-
ing lymphocyte egress and immunosuppression, there-
fore being effective for the palliation of this CNS
inflammatory syndrome [12,13]. Nevertheless, this
drug, as it happens with signalling lipids, also
enhances SNARE complex formation and promotes
the release of neurotransmitters in neuroendocrine cel-
lular models [14]. Here, we review the molecular mech-
anisms and the exocytotic steps regulated by signalling
lipids and related molecules affecting the secretory
activity of neuronal and neuroendocrine cells.
The traditional and new role of lipids
in exocytotic membrane fusion
Neurotransmitters and hormones are stored in special-
ized vesicles. The release of these active substances
requires the fusion of the membrane forming these
vesicles with the plasma membrane during exocytosis
[15–17]. The process initiates with the formation of a
structure called the fusion pore, formed with lipids
from the opposite membranes [6,18,19].
As the formation of the fusion pore requires the
active reorganization of lipids to overcome energy bar-
riers, the actual ‘proteocentric’ vision claimed catalytic
proteins as sculptors of the lipid bilayers, giving the
lipids a mere passive structural role. Since lipid bilay-
ers need to adopt curved shapes during membrane
fusion, either proteins or lipids could help in the spon-
taneous bending, therefore the shape of the lipids
forming the fusing leaflets have an important role in
the facilitation of exocytosis [20]. In this sense, conic
shape lipids with larger or smaller heads comparing
with its inner fatty acid chains will facilitate membrane
curvature and in consequence there is a large number
of evidences supporting this ‘shaping’ role [7,20–23],
especially for lysophospholipids regulating the secre-
tion in neuroendocrine cells (see Fig. 1) [24,25].
Lipids can additionally influence exocytosis by
aggregating into specific microdomains that recruit
proteins required for neurosecretion. In this sense, it is
well-established that phosphatidyl inositol 4,5-bipho-
sphate (PIP2) is a specific requirement for exocytosis
(Fig. 1) [26], being recruited in secretory sites by intra-
cellular calcium elevations during cell stimulation [27].
Today, these initial studies have been supported by
recent studies proving that PIP2 coordinates the
translocation of secretory vesicles to their docking sites
on the plasma membrane in a Cdc42-dependent man-
ner [28,29]. In that way, forms clusters that, in addi-
tion to nucleation of the formation of F-actin bundles,
also interact with SNARE proteins [30], and in conse-
quence act as a beacon for vesicle guidance to active
secretory sites (Fig. 1).
In addition, other membrane constituents, such as
cholesterol, are essential for maintaining the hetero-
geneities in the plasma membrane that accumulate
secretory proteins such as syntaxin-1 in well-defined
clusters within so called lipid rafts [31–35].
Finally, lipids are incorporated into secretory pro-
teins to modify them and affect in that way either the
location or the activity. This post-translation modifica-
tion consists frequently in an acylation by the incorpo-
ration of palmitate, a saturated 16-carbon fatty acid,
into cysteine residues [36], and the major target in neu-
roendocrine cells is the SNARE protein synaptosomal-
associated protein of 25 kDa (SNAP-25) [37–39].
Palmitoylation of SNAP-25 in four central residues
(Fig. 1)[38], is likely to enhance the clustering of
SNAP-25 in cholesterol and sphingomyelin rich lipid
rafts and in that way may be a cohesive factor in the
formation of exocytotic active sites [33,40,41]. The
exact role of SNAP-25 palmitoylation is unclear, since
some studies indicate that it is a major factor support-
ing the secretory activity of this protein transmitting
to the fusing membranes the proper forces generated
during SNARE complex assembly or zippering [42],
whilst others suggest that the palmitoylation serves a
more conventional role in membrane anchoring [37].
It is important to mention that SNAP-25 is not the
only protein relevant for exocytosis that is pamitoy-
lated, as synaptobrevin 2, present in the vesicular
membrane could be modified by palmitic acylation
during brain development, as this modification is only
found in adults and not in embryonic rats [43]. In
addition, synaptotagmin 1, an essential calcium sensor
[44], is palmitoylated in five residues near the trans-
membrane domain [38]. Finally, cystein string protein
(CSP), a molecular chaperone helping in protein fold-
ing [45], is heavily palmitoylated in 14 cystein residues
and it has been found to be important for the secretory
process in neuronal and endocrine models [46–48].
As could be derived from the multiple roles assumed
by lipids as mentioned above, their function in exocy-
tosis is far more complex than the deduced from being
the basic structural elements forming membranes, and
this is further evidenced with recent data on the direct
modulation of the secretory machinery by signalling
lipids.
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Signalling lipids, new players in the
regulation of exocytosis
In neuroendocrine cells SNAREs proteins are located
in the fluid mosaic of the plasma membrane composed
of a diversity of lipids including phospholipids, sphin-
golipids and cholesterol [49], and stabilized by a
matrix of cytoskeletal elements forming the dynamic
cytoarchitecture of active sites [50,51]. In this environ-
ment, the activity of phospholipases could release
either saturated and also polyunsaturated fatty acids
(PUFAs) that normally are present in the sn-2 position
[52], and often, the released PUFAs could act as a
intracellular messengers regulating a diversity of cellu-
lar processes including exocytosis [25,53–57]. Specifi-
cally, phospholipase type A2 (PLA2) acting in the sn-2
site release lysophospholipids and free unsaturated
fatty acids, and the latter ones can diffuse into cytosol
where they interact with their targets of action, likely
in hydrophobic domains [58,59]. Certainly, different
elements of the molecular machinery of exocytosis are
among these targets, since it has been demonstrated
that inhibitors of PLA2 influence exocytosis in neu-
roendocrine cells [57,60,61], and addition of snake
PLA2 neurotoxins alter secretion in neuronal [62–65]
and chromaffin cells [66,67] via a variety of mecha-
nisms. In the latter secretory model, it is quite illustra-
tive that other phospholipases such as phospholipase
C (PLC) and phospholipase D (PLD) have been impli-
cated in catecholamine secretion [68–71], in this cases
the activation of PKC by diacylglycerol mediates the
PLC pathway [70,72], whereas the generation of phos-
phatidic acid seems to be associated with PLD sig-
nalling driving the enhancement of exocytosis
[68,69,71,73]. In all these cases the generation of a sig-
nalling lipid has been demonstrated to be essential to
Fig. 1. Lipids regulate exocytosis by different mechanisms. This figure presents different ways used by lipids to regulate vesicle fusion
during exocytosis. Lipids, such as lysophosphatidic acid present a conic shape that facilitate membrane curvature during exocytosis
influencing this process in consequence (represented in green). In addition lipids could be incorporated into the proteins constituting the
molecular machinery to for example stabilize membrane attachments as it happens with palmitoylation of SNAP-25, synaptobrevin,
synaptotagmin, CSP and Rab proteins (in blue in the figure). Other lipids such PIP2 could be acting as molecular beacons for the guidance
of the vesicles to secretory active sites (in yellow). Finally, signalling lipids could interact directly with SNARE proteins and promote vesicle
fusion. This is the case of AA influencing syntaxin 1 activity or sphingosine facilitating an open conformation of synaptobrevin II and
favouring SNARE complex formation (in red in the figure).
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influence different elements of the secretory pathway.
From now on we will focus on the action of these
compounds over the molecular constituents of the exo-
cytotic molecular machinery.
Signalling lipids interact directly with
the fusion machinery
After the release of signalling lipids such AA or sphin-
gosine from the lipid bilayer, these lipids could diffuse
and interact with SNARE proteins and therefore regu-
late the activity of these fusogenic proteins. The first
report of a direct interaction of signalling lipids with
SNAREs was reported in 2005 when the direct admin-
istration of AA or the treatment with PLA2s was
demonstrated to enhance the formation of the SNARE
complex in synaptic membrane preparations [9]. One
of the most remarkable characteristic of this potentia-
tion is that AA could interact with syntaxin-1 even in
the presence of Munc-18 which stabilizes a closed con-
formation of syntaxin-1 (Fig. 1) [8,9], this may suggest
that this lipid could penetrate into the hydrophobic
zones of syntaxin-1 without altering the native dimers
of syntaxin-1/Munc-18. This may be a basic principle
of AA activation of syntaxins since it was also
reported to occur with the syntaxin-3 isoform [8].
The importance of this mechanism for the regulation
of syntaxins was later stressed when we found that the
protein a-synuclein, implicated in the phatogenesis of
Parkinson’s disease, was found to sequester AA pre-
venting the enhancement of SNARE complex forma-
tion caused by this lipid [74], thus providing new
insights into the alteration of neurotransmission by the
pathogenic a-synuclein.
More recently, in screening the ability of a diversity
of lipids in modulating the formation of SNARE com-
plexes, we found that only sphingosine and some
derivatives were able to activate synaptobrevin 2 to
engage SNAP-25-syntaxin heterodimers acting in the
interphase between vesicular lipids and synaptobrevin
(Fig. 1) [10]. This effect was dose-dependent with a
EC50 ~ 10 lM and resulted in the enhancement of the
exocytosis in neuronal and neuroendocrine cellular
models. Furthermore, in neurons from synaptobrevin
2 knockout mice no modulation of exocytosis by sph-
ingosine was observed, thus stressing the implication
of this vesicular SNARE in mediating the action of
sphingosine activating neurosecretion [10]. Analysis of
sphingosine-related compounds revealed two critical
features of sphingosine to promote SNARE complex
formation and enhance exocytosis: the length of the
carbon chain and the positive charge of sphingosine.
Furthermore, L-sphingosine was as active as the
D-sphingosine suggesting that it may act by perturbing
the local environment of synaptobrevin [10].
In order to demonstrate that the endogenous sphin-
gosine production could mimic these results, the activ-
ity of external sphingomyelinases (SMase) and
intracellular ceramidases releasing sphingosine into the
cytosol in isolated nerve terminals [10], or cultured
chromaffin cells [54,75] was tested on potentiation of
exocytosis. The obtained results support this mecha-
nism and further implicate synaptobrevin 2 since the
treatment of the cells with Botulinum Neurotoxin type
D, cleaving vesicular synaptobrevin, prevented the
enhancement of neurosecretion due to the production
of sphingosine and derivatives.
It is important to note, however, that Camoletto
and co-workers [76] found that sphingosine may act
on syntaxin-1 facilitating the engagement with Munc-
18. Thus, this mechanism will decrease the number of
docked vesicles and increase paired-pulse facilitation in
neurons.
In conclusion, there is substantial evidence for a
direct interaction of signalling lipids with a variety of
SNAREs and further work is needed to establish the
precise molecular mechanisms involved in such interac-
tions associated with the regulation of the secretory
activity of neuronal and neuroendocrine cells.
Signalling lipids increase the
frequency and quantal release of
neurotransmitters
How do signalling lipids affect the exocytotic process?.
Well, if these lipid messengers potentiate the formation
of SNARE complexes it is predicted that they will
enhance secretion, and in the case of sphingosine, this
has been demonstrated in melanotrophs, chromaffin
cells, isolated nerve terminals and hippocampal neurons
[10]. Since, exocytosis is a multistep process involving
the translocation of vesicles to the plasma membrane,
the ‘priming’ or maturation of the vesicles to be in a
‘ready-releasable’ state, and the final fusion of the mem-
branes to release the vesicular content [15,17,77–79], it
is important to define the different stages of this process
altered by signalling lipids and this required the use of
biophysical techniques with the capability of analysing
fusion at the level of individual vesicles.
In 2013, two groups used such techniques to study
the effect of sphingosine over the exocytosis in differ-
ent cellular systems. Zorec’s group from Ljubljana
University applied the capacitance technique [80,81] to
resolve unitary exocytotic events in pituitary lac-
trotrophs finding that sphingosine increases the fre-
quency of the fusion of small vesicles and also larger
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dense vesicles [82]. They also observed that sphin-
gosine promoted the full fusion of large vesicles
whereas smaller vesicles tent to fuse in the ‘kiss and
run’ mode [83], only partially releasing their vesicular
content, leading to the conclusion that the vesicle size
was an important factor favouring the shift of fusion
mode caused by sphingosine.
Simultaneously, our group at the Institute of Neuro-
sciences of Alicante performed experiments in adreno-
medullary chromaffin cells, using the amperometry
technique [84] to detect the release of catecholamines
from individual fusion events by their oxidation at the
tip of a carbon fibre [54]. In our study, sphingosine and
derivatives were produced by SMase treatment of the
cells, and resulted in the increase of the amount of cate-
cholamines released in individual fusions with detection
of changes in the kinetics of the process suggesting
changes in the mode of fusion of the vesicles. In addi-
tion, AA was also employed to show a 2–3 fold increase
in the amount of catecholamines release per individual
event, again implying that in the control situation and
with chromaffin cells stimulated by depolarization, the
release is suboptimal (kiss and run mode) and that sig-
nalling lipids promoted the full granular fusion.
Later on, the whole cell and on-cell capacitance
techniques were used to study if sphingomyeline
derivatives affect the release of different types of vesi-
cles in chromaffin cells [75], and the results demon-
strated an increase in the frequency of the release of
small vesicles as well as large dense granules in agree-
ment with the results obtained in lactotrophs.
In conclusion, the experiments performed with tech-
niques allowing the high temporal resolution of secre-
tory events in neuroendocrine cells demonstrated that
signalling lipids increase the frequency of fusion of
clear small vesicles as well as large dense granules and
that these lipids are able to favour a change in the
mode of exocytosis from the transient fusion pore
opening characteristic of the ‘kiss and run’ mode to
the full extent fusion collapsing the vesicle membrane.
FTY-720, an analogue of sphingosine
revealed multiple possible targets for
signalling lipids derivatives
The sphingolipid signalling pathway is important for
the regulation of multiple physiological processes in
the brain [85–89], including neurotransmission [52,90–92],
and for the pathologies associated with neuronal disor-
ders [88,93–95]. Therefore, molecules designed to mimic
these compounds could interfere with the normal and
pathological neuronal pathways and be useful as
potential pharmacological tools. This is the case with
FTY-720 also known as Fingolimod, an analogue of
sphingosine that has been used extensively as an
immunosuppressant agent [96], and moreover, it has
been recently approved for treatment of relapsing remit-
ting multiple sclerosis [11,97]. FTY-720 crosses the
blood brain barrier [98], and like sphingosine is phos-
phorylated, allowing it to interact with the receptors of
sphingosine-1P mediating the egression of lymphocytes
and causing immunosuppression (Fig. 2) [99].
Very recently it was demonstrated that FTY-720
readily imitates sphingosine in its ability to interact
with synaptobrevin promoting SNARE complex for-
mation and increasing exocytosis from neuronal and
neuroendocrine cellular systems [14]. This drug at con-
centrations around 10–20 lM (very similar to the sph-
ingosine range), was able to enhance the frequency of
glutamate release from rat synaptosomes, secretion
from melanotrophs and chromaffin cells, and the neu-
rotransmission from cultured rat hippocampal neurons
(Fig. 2). In addition, FTY-720, also shares with sphin-
gosine the modulation of the mode of exocytotic
fusion, as it augments the amount of neurotransmitter
release per individual fusion event [14].
Nevertheless, FTY-720 could be having a complex
action on secretion, as it has been found to inhibit the
release of cargo from different types of vesicles in cul-
tured rat astrocytes due to a decrease in vesicle mobility
[100]. Both sphingosine and FTY-720, caused an
impaired access of the vesicles to releasable sites, an effect
that has been associated with an alteration of calcium
dynamics by signalling lipids in this cellular system [101].
The results from astrocytes are in apparent contra-
diction with those reported in neuroendocrine systems,
nevertheless, we have found recently that in chromaffin
cells FTY-720 has a dual effect on catecholamine
release. In this neuroendocrine model, incubation with
FTY-720, increases the frequency of vesicle fusions
during the first round of cell stimulation by depolar-
ization but decreases the amount of vesicles recruited
in subsequent stimulations, (V. Garcia-Martinez, J.
Villanueva, Y. Gimenez-Molina & L. M. Gutierrez,
unpublished results). Furthermore, by using FRET, we
have observed that FTY-720 interacts at the molecular
level with SNARE clusters in chromaffin cells as was
previously described for sphingosine and AA [54]. In
addition, FTY720 could also interact with F-actin gov-
erning the motion of the vesicles in the close proximity
of secretory sites [102,103]. Thus, FTY-720 seems to
influence secretion through interaction with several cel-
lular targets, and remarkably we have found recently
by using electron microscopy that this compound also
promotes the homotypic fusion of vesicles and the het-
erotypic fusion of vesicles and mitochondria in the
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cytosol of chromaffin cells (Y. Gimenez-Molina, V.
Garcia-Martinez, J. Villanueva, B. Davletov & L. M.
Gutierrez, unpublished results, Fig. 2), these intriguing
findings may suggest that the characterization of the
cellular targets of FTY-720 is an open research subject
requiring further experimentation.
Conclusions and perspectives
In conclusion, our understanding of the role of lipids
in the process of the release of neurotransmitters and
hormones by the exocytotic fusion of the vesicular and
plasma membranes has evolved drastically in the last
Fig. 2. Targets of the sphingomimetic drug FTY-720. The analogue of sphingosine FTY-720 was first characterized as an immunosuppressor
drug when in its phosphorylated form binds to sphingosine 1-P receptors causing lymphocyte egress (A). This drug has been proved to
mimic sphingosine activating synaptobrevin II and increasing the formation of the SNARE complex leading to the enhancement of
neurosecretion (B). In addition, FTY-720 has been shown to inhibit the motion of the vesicles in astrocytes and chromaffin cells interacting
with the F-actin cytoskeleton (C). Finally, and very recently, we have observed that FTY-720 could induce the homotypic fusion of vesicles
and the heterotypic fusion of mitochondria with vesicles in the chromaffin cell cytosol (D, mixed organelles product of vesicle-mitochondria
fusion).
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20 years from being the mere structural components of
these membranes to a more active and direct function
in modulation of the proteins constituting the molecu-
lar machinery of membrane fusion. Today, it is well-
accepted that in addition to this structural role, certain
lipids such lysophospholipids could be helping to
adopt the membrane curvature favouring membrane
fusion [24,25], lipids such PIP2 are produced and
transported to the active sites to act as a molecular
beacons attracting vesicle movement towards these
specific sites for preferential fusion [30], and proteins
are modified by addition of palmitate chains to sup-
port membrane anchoring and stabilization [37].
Moreover, lipids such AA and sphingosine, pro-
duced by the action of phospholipases and diffusing
into the cytosol acting as signalling lipids have been
shown to interact with SNARE proteins and activate
the formation of the fusogenic SNARE complex there-
fore facilitating neurotransmission in neuronal and
neuroendocrine cells [8–10]. Interestingly, these lipids
modulate not only the frequency of vesicle fusion but
also the fusion pore behaviour promoting the full
fusion mode over the partial release by the ‘kiss and
run’ mode [54,82], thereby suggesting that these sig-
nalling lipids could be fine-tuning the amount of neu-
rotransmitter release per secretory event to adapt to
specific functional requirements.
The importance of these signalling lipids was stressed
when FTY-720 (Fingolimod), a structural analogue of
sphingosine was approved as the first drug for oral
treatment of relapsing multiple sclerosis [11]. This ther-
apeutic use is based on the immunosupression proper-
ties of the phosphorylated form of FTY-720 binding to
sphingosine 1-P receptors and supressing lymphocyte
egress [96]. In recent years, FTY-720 has been found to
affect a plethora of physiological processes including
neuronal gene expression, axonal growth, and regener-
ation [104], suggesting that this drug may influence a
variety of aspects of the physiology of neurons. There-
fore, the finding that FTY-720 mimics the properties of
signalling lipids towards the activation of SNAREs
and the parallel potentiation of exocytosis was funda-
mental to understand the possible mechanisms underly-
ing the role of FTY-720 in neuronal function.
The results obtained with FTY-720 may indicate
that signalling lipids and related drugs could be acting
on multiple targets involved in different cellular and
pathological processes explaining why this compound
stimulates neuronal function and regeneration [104],
and benefits neuroprotection in murine disease models
[105], ischaemia [106,107], excitotoxicity [108], and can
even improve the recovery of memory and learning in
neurological disorders [109–112].
In summary, the study of the molecular mechanisms
associated with the physiological regulation of neu-
rosecretion by signalling lipids promises not only the
understanding of basic mechanisms governing the
secretory activity in neuronal and neuroendocrine cells
but also the possible design of new therapeutic agents
against neurological disorders.
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